9月24日，北陆药业盘中上涨2.04%，截至14:13，报9.00元/股，成交1.08亿元，换手率2.16%，总市值 50.66亿元。 今年以来北陆药业已经2次登上龙虎榜，最近一次登上龙虎榜为6月17日，当日龙虎榜净买入3375.52万 元；买入总计9540.19万元 ，占总成交额比11.17%；卖出总计6164.67万元 ，占总成交额比7.22%。 资料显示，北京北陆药业股份有限公司位于北京市海淀区西直门北大街32号枫蓝国际写字楼A座7层， 成立日期1992年9月5日，上市日期2009年10月30日，公司主营业务涉及对比剂系列、中枢神经类和降糖 类药品的生产、研发与销售。主营业务收入构成为：对比剂63.33%，中成药22.09%，降糖药12.75%， 其他(补充)1.83%。 北陆药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：原料药、医药电商、中 药、基因测序、生物医药等。 截至6月30日，北陆药业股东户数4.39万，较上期增加43.48%；人均流通股11256股，较上期减少 29.84%。2025年1月-6月，北陆药业实现营业收入5.84亿元，同比增长23.27%；归母净利润2996 ...

9月24日午后，制药板块继续上攻，全市场唯一药ETF（562050）冲高逾2%。 成份股方面，创新药概念领涨，信立泰和甘李药业双双涨停封板！权重股恒瑞医药、百济神州等均飘 红。中药股亦表现不俗，太极集团、东阿阿胶、达仁堂集体涨超2%。 | 分时 多日 1分 5分 · | | | | F9 盘前盘后 露加 九井 画线 工具 @ (2) > | | | | | | | GETF 1 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1,127 | | | 562050[药ETF] 14:06 价 1.127 温康 0.024(2.18%) 均价 1.117 成交盘 .. | | | 1 2.18% | | 1.127 | +0.024 +2.18% | | EGONED 7 | | | 1,119 | | | WAND W | | | 1,45% | | SSE CNY 14:06:07 交易中 | | | | 1 . 4 | | | | | | | | | 净值出现 | | 华富中证制药ET ...

9月24日，陇神戎发盘中上涨2.10%，截至13:38，报9.71元/股，成交4516.86万元，换手率1.55%，总市 值29.45亿元。 资金流向方面，主力资金净流入156.88万元，特大单买入100.63万元，占比2.23%，卖出0.00元，占比 0.00%；大单买入842.75万元，占比18.66%，卖出786.50万元，占比17.41%。 陇神戎发所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：甘肃国资、医药电商、中 药、小盘、医疗器械等。 截至9月10日，陇神戎发股东户数2.78万，较上期减少0.71%；人均流通股10853股，较上期增加0.71%。 2025年1月-6月，陇神戎发实现营业收入4.96亿元，同比减少9.91%；归母净利润2795.61万元，同比增长 30.31%。 分红方面，陇神戎发A股上市后累计派现4264.16万元。近三年，累计派现2426.76万元。 机构持仓方面，截止2025年6月30日，陇神戎发十大流通股东中，汇添富中证中药ETF（560080）位居 第六大流通股东，持股97.85万股，相比上期减少10.16万股。 责任编辑：小浪快报 陇神戎发今年以来股价涨1 ...

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 252.81%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its listing date on November 16, 2017 [1]. - The company's main business involves the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The revenue composition is as follows: Children's medicine 61.12%, Chronic disease medicine 22.71%, Others 16.17% [1]. Financial Performance - For the first half of 2025, Yipinhong reported operating revenue of 584 million yuan, a year-on-year decrease of 36.02%, and a net profit attributable to shareholders of -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - The company has distributed a total of 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed in the last three years [3]. Shareholder Information - As of August 31, the number of Yipinhong's shareholders was 21,400, an increase of 0.49% from the previous period, with an average of 19,553 circulating shares per person, a decrease of 0.49% [2]. - As of June 30, 2025, Yipinhong's top ten circulating shareholders included E Fund Medical Healthcare Industry Mixed A as the eighth largest shareholder, holding 4.3661 million shares, while Hong Kong Central Clearing Limited exited the top ten list [3]. Market Activity - On September 24, Yipinhong's stock price rose by 2.02% to 60.19 yuan per share, with a trading volume of 218 million yuan and a turnover rate of 0.88%, resulting in a total market capitalization of 27.187 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.5761 million yuan [1].

Core Viewpoint - Kanghong Pharmaceutical's stock has shown significant volatility, with a year-to-date increase of 96.63% but a recent decline in the last five and twenty trading days [1][2]. Group 1: Stock Performance - As of September 24, Kanghong Pharmaceutical's stock price was 37.36 CNY per share, with a market capitalization of 34.42 billion CNY [1]. - The stock experienced a net inflow of 5.30 million CNY from main funds, with large orders accounting for 13.33% of purchases [1]. - The stock has seen a 5.70% decline over the last five trading days and an 8.27% decline over the last twenty trading days [1]. Group 2: Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.45 billion CNY, representing a year-on-year growth of 6.95%, and a net profit of 730 million CNY, up 5.41% year-on-year [2]. - The company has distributed a total of 2.04 billion CNY in dividends since its A-share listing, with 1.04 billion CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of September 10, the number of shareholders for Kanghong Pharmaceutical was 24,700, a decrease of 1.19% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.21% to 27,778 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several mutual funds, with notable changes in their holdings [3].

中关村所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：中药、养老产业、高血压 防治、小盘、低价等。 截至6月30日，中关村股东户数7.06万，较上期减少0.14%；人均流通股10636股，较上期增加0.81%。 2025年1月-6月，中关村实现营业收入12.39亿元，同比减少2.71%；归母净利润3880.89万元，同比增长 6.65%。 分红方面，中关村A股上市后累计派现2.70亿元。近三年，累计派现0.00元。 9月24日，中关村盘中上涨2.19%，截至10:55，报5.13元/股，成交3125.25万元，换手率0.82%，总市值 38.64亿元。 资金流向方面，主力资金净流出268.66万元，大单买入395.22万元，占比12.65%，卖出663.88万元，占 比21.24%。 中关村今年以来股价涨7.77%，近5个交易日跌4.65%，近20日跌7.23%，近60日跌5.87%。 资料显示，北京中关村科技发展(控股)股份有限公司位于北京市朝阳区霄云路26号鹏润大厦B座22层， 成立日期1999年6月8日，上市日期1999年7月12日，公司主营业务涉及医药业务、混凝土业务、地产业 务。主营 ...

诚意药业今年以来股价涨78.88%，近5个交易日跌2.97%，近20日跌5.77%，近60日涨28.04%。 今年以来诚意药业已经4次登上龙虎榜，最近一次登上龙虎榜为8月6日，当日龙虎榜净买入1.38亿元； 买入总计3.22亿元 ，占总成交额比21.10%；卖出总计1.85亿元 ，占总成交额比12.10%。 资料显示，浙江诚意药业股份有限公司位于上海市闵行区申虹路988弄富力悦都20幢9号7层，成立日期 2001年6月22日，上市日期2017年3月15日，公司主营业务涉及化学药品原料药及制剂的研发、生产和销 售。主营业务收入构成为：制剂80.99%，原料药17.46%，中药0.63%，中间体及其他0.50%，食品 0.31%，其他(补充)0.10%。 9月24日，诚意药业盘中上涨2.06%，截至10:09，报13.38元/股，成交3814.40万元，换手率0.88%，总市 值43.79亿元。 资金流向方面，主力资金净流入64.81万元，大单买入700.71万元，占比18.37%，卖出635.90万元，占比 16.67%。 截至6月30日，诚意药业股东户数1.57万，较上期减少5.15%；人均流通股20888股 ...

佐力药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：基因测序、医药电商、中 药、生物医药、创新药等。 9月24日，佐力药业盘中上涨2.05%，截至10:16，报17.92元/股，成交8322.21万元，换手率0.78%，总市 值125.69亿元。 资金流向方面，主力资金净流入1198.85万元，特大单买入0.00元，占比0.00%，卖出106.94万元，占比 1.28%；大单买入2414.17万元，占比29.01%，卖出1108.38万元，占比13.32%。 佐力药业今年以来股价涨21.34%，近5个交易日跌0.78%，近20日跌6.42%，近60日涨2.40%。 资料显示，浙江佐力药业股份有限公司位于浙江省德清县阜溪街道志远北路388号，成立日期2000年1月 28日，上市日期2011年2月22日，公司主营业务涉及药用真菌乌灵系列和百令片产品、中药饮片及中药 配方颗粒的研发、生产与销售。主营业务收入构成为：乌灵系列56.07%，中药饮片系列21.85%，其他 产品10.11%，百令系列7.08%，中药配方颗粒4.62%，其他(补充)0.26%。 责任编辑：小浪快报 截至6月30日，佐力药业股 ...

Core Insights - Kanghui Pharmaceutical's stock price increased by 2.01% on September 24, reaching 22.33 CNY per share, with a total market capitalization of 2.23 billion CNY [1] - The company has experienced a year-to-date stock price increase of 55.50%, but has seen a decline of 5.66% over the last five trading days [2] Financial Performance - For the first half of 2025, Kanghui Pharmaceutical reported a revenue of 248 million CNY, a year-on-year decrease of 6.83%, and a net profit attributable to shareholders of -40.20 million CNY, a significant decline of 362.01% [2] - The company has not distributed any dividends in the last three years, with a total payout of 54.23 million CNY since its A-share listing [3] Shareholder Information - As of June 30, the number of shareholders increased by 37.26% to 12,000, while the average number of tradable shares per shareholder decreased by 27.14% to 8,326 shares [2]

Group 1 - The stock price of Lizhu Group fell by 2.01% on September 23, reaching 37.95 CNY per share, with a trading volume of 1.58 billion CNY and a turnover rate of 0.71%, resulting in a total market capitalization of 34.31 billion CNY [1] - Year-to-date, Lizhu Group's stock price has increased by 2.79%, but it has decreased by 5.88% in the last five trading days and by 9.15% in the last 20 days, while it has risen by 3.83% over the last 60 days [1] - As of June 30, 2025, Lizhu Group's revenue was 6.272 billion CNY, a year-on-year decrease of 0.17%, while the net profit attributable to shareholders was 1.281 billion CNY, reflecting a year-on-year increase of 9.40% [2] Group 2 - Lizhu Group's main business revenue composition includes chemical preparations (52.14%), APIs and intermediates (26.49%), traditional Chinese medicine preparations (12.75%), diagnostic reagents and equipment (5.97%), and biological products (1.51%) [2] - The company has distributed a total of 10.523 billion CNY in dividends since its A-share listing, with 3.721 billion CNY distributed in the last three years [3] - As of June 30, 2025, the number of shareholders in Lizhu Group was 46,400, a decrease of 11.30% from the previous period, while the average circulating shares per person increased by 12.71% to 12,581 shares [2]